Watch Dr Christopher Cannon discuss his study: Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation
Register your email and provide your feedback
To help measure the effectiveness of this NOAC Education module, please enter your email below to take part in a short follow-up survey
In patients with atrial fibrillation who have had a percutaneous coronary intervention, the current standard practice is to prescribe “triple therapy” i.e. warfarin plus two antiplatelet agents including an aspirin. However, this is associated with a high risk of bleeding. This ground-breaking trial compares triple therapy with “dual therapy” (dabigatran plus one antiplatelet agent).